Consun Pharmaceutical Group Limited executed an on-market share repurchase on 17 June 2026, purchasing 168,000 ordinary shares for HKD 2.22 million at prices ranging between HKD 13.20 and HKD 13.24 per share. The volume-weighted average price was HKD 13.2185.

Following the transaction: • Issued shares (excluding treasury shares) decreased by 0.02 % from 840.01 million to 839.84 million. • Treasury share holdings rose from 1.54 million to 1.70 million shares, keeping total issued shares unchanged at 841.55 million.

Mandate utilisation and limits: • Repurchases are conducted under the mandate approved on 26 May 2026, which authorises the company to buy back up to 84.12 million shares. • Cumulative buybacks under this authority now total 1.36 million shares, equivalent to 1.62 % of the shares outstanding on the mandate date. • In line with Hong Kong listing rules, Consun Pharmaceutical is restricted from issuing new shares or selling treasury shares until 17 July 2026.

All repurchase procedures were confirmed as compliant with the Hong Kong Stock Exchange’s Main Board Rules and relevant regulatory requirements.